Late-breaking Phase 3 data at AAD 2022 show Dupixent® significantly improved signs and symptoms of prurigo nodularis Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three. | March 26, 2022
Investegate announcements from Sanofi - Aventis Groupe, Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
"The efficacy observed after only 4 weeks is exciting; . an effective non-steroidal, non-injectable therapy without black box warnings or laboratory monitoring is pretty much the holy grail."
Second positive Phase 3 Dupixent (dupilumab) trial confirms significant improvements for patients with prurigo nodularis Dupixent is the first and only medicine to demonstrate positive Phase
/PRNewswire/ Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of.